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Introduction
Peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS) constitute a heterogeneous group of nodal and extranodal mature T-cell lymphomas that do not correspond to any of the specifically defined entities of mature T-cell lymphoma in the current WHO Classification system [1] . PTCL-NOS account for 25.9% of PTCLs according to the International Peripheral T-cell Lymphoma Project [2] and 7.21% of all lymphomas in Japan [3] .
PTCL-NOS include lymphomas that can be categorized into various groups genetically and biologically; therefore, this category has been referred to as a "wastebasket" category [4] . Histologically, PTCL-NOS show paracortical or diffuse infiltrates, with effacement of the normal lymph-node architecture. In most cases, numerous medium-sized or large cells with many mitotic figures are noted. In rare cases, small lymphoid cells predominate, but the cells show atypia and have irregular nuclei.
Although PTCL-NOS is a heterogeneous category, it is generally thought that PTCL-NOS are aggressive lymphomas characterized by a poor response to therapy, frequent relapses, and a low 5-year overall survival rate [5] .
In the present study, we described a group of 10 patients that was morphologically and Hayashi, et al 7 phenotypically unique, having small, monotonous lymphoid cells characterized by slight nuclear atypia, a low Ki-67 labeling index (LI), and good prognosis compared to those of typical PTCL-NOS patients.
To the best of our knowledge, no previous clinicopathological studies have focused on these unique T-cell lymphomas, excluding a few case reports [6, 7] . The immunohistochemical and genotypic characteristics of this disease were examined in the current study, and we attempted to determine the clinical significance of these findings during the clinical follow-up.
Materials and Methods

Patient selection and clinical data
We chose 10 PTCL-NOS patients characterized by an infiltrate of monotonous, small-sized lymphoid cells with slight nuclear atypia and a low Ki-67 LI (<5%), from among 277 cases of PTCL-NOS recorded in the 2006-2011 pathology consultation files of the Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. Among all 277 cases, no patients had the same histopathology but a higher Ki-67 LI. Fourteen of the 277 cases had small to medium 8 sized lymphoid cells with irregular nuclei, and showed high Ki-67 LI (>30%). Therefore, we excluded these cases in the present study. There was no case composed of large-sized lymphoid cells and showing a low Ki-67 LI. Because the samples of all 10 patients that we included had a Ki-67 LI of 5% or less in our study, we defined the cut-off as 5%, although it is commonly placed at 30% [8] . Clinical data were available for all patients. We collected data on age, gender, complete blood count, lactate dehydrogenase (LDH) level, B symptoms, disease at other sites, bone marrow involvement, performance status (PS), Ann Arbor stage [9] , international prognostic index (IPI) [10] , prognostic index for PTCL-unspecified (PIT) [11] , history of prior immunosuppressive therapy or immune system disorder, type of treatment, response to therapy, date of last follow-up, and status. HIV-positive or human T-cell leukemia virus-positive patients were excluded. Informed consent for examination was obtained for the use of all samples.
Immunohistochemistry and hybridization studies
Tissue samples were fixed in 10% formalin and embedded in paraffin. Staining was performed using paraffin sections with an automated Bond-max stainer (Leica Hayashi, et al 9 Biosystems, Melbourne, Vic., Australia). The primary antibodies and probes used are summarized in Table 1. For CD20, CD3, CD5, CD7, CD4, CD8, CD79a, CD45RO,   CCR7, CD62L, PD1, CD56, CD57, CXCL13, granzyme B, TIA-1, TCRγ, TCRδ, and TCRβ antigens, positivity was identified when at least 30% of the lymphoma cells were positive for their respective antibodies. The Ki-67 LI was determined by counting at least 1,000 tumor cells in each sample, and the index was calculated as a percentage.
For flow cytometry (FCM), the following antibodies were used: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD22, and CD23, along with Igκ and Igλ light chains.
For the indirect double immunofluorescence study, paraffin sections were stained with CD3 and CD20. The following primary antibodies (clone, dilutions) were used: CD20 (L26, 1:200; Novocastra, Newcastle-upon-Tyne, UK) and CD3 (rabbit polyclonal, 1:100; Abcam, Tokyo, Japan). The indirect double immunofluorescence study was performed according to standard procedures, as described previously [12] .
Molecular genetic analysis
Molecular genetic analysis was performed using polymerase chain reaction (PCR) or Southern blot hybridization. PCR was used in the analysis of gene rearrangements of both TCR and the immunoglobulin heavy chain (IgH). PCR was performed according to standard procedures, as described previously [13] [14] [15] [16] . For Southern blot hybridization, high-molecular-weight genomic DNA was extracted from fresh tissue taken from the patients and used for the detection of TCRγ gene rearrangements or IgH gene rearrangements, according to a method described previously [17] .
Results
Patient summary
The clinical features of the 10 patients are summarized in Table 2 . The age of the patients (5 men and 5 women) ranged from 41 to 82 years, with a median age of 61.5 years. Eight patients showed extranodal site involvement, with the extranodal site being the spleen in most cases (5 patients), followed by the thyroid gland (3 patients).
Additionally, in 2 of 5 patients who had an affected spleen, the disease was localized to that organ. Those patients with thyroid gland involvement also demonstrated involvement of the regional lymph nodes (2 patients) or systemic lymph nodes (1 patient). Three of 10 patients had systemic lymph node involvement. Bone marrow Compared to the study of PTCL-NOS by the international PTCL-NOS project [5] , our patient series had low IPI scores (p < 0.001), low PIT group scores (p = 0.002), and a normal LDH level (p = 0.035; Table 3 ). Furthermore, compared with another report that described clinical information in more detail [18] , our patient series had low clinical stages (p = 0.025), low IPI scores (p = 0.015), and a normal LDH level (p = 0.025; Table 3 ).
Morphological and immunophenotypic features
Regardless of whether the lesion was nodal or extranodal, all samples presented diffuse infiltrate of small lymphoid cells (Figure 1 a- did not increase. All samples in the study were negative for CD79a, CD56, TCRδ, TCRγ, and EBER ISH. An overview of marker expression is presented in Table 4 , and Figure 1 g-x shows the immunohistochemical staining of patient no. 9. Mitosis was very rare, and Ki-67 LI was low (range, 0.28-3.04%; mean, 1.05%; Table 4 ).
Five samples had CD20 expression. Figure 2 a-d shows CD20 expression, as measured using flow cytometry, and the double immunofluorescent study of CD3 (green) and CD20 (red) in patient no. 7. We found that CD20 was coexpressed in CD3-positive tumor cells.
Molecular genetic findings
TCRγ chain and/or TCRα-βchain gene rearrangements were detected in all 10 patients.
In 7 of these patients, these rearrangements were detected using PCR analysis; in the remaining 3 patients, the rearrangements were detected using Southern blot hybridization ( Figure 3 a-b) . However, we could not detect any immunoglobulin heavy-chain gene rearrangements in any of the 10 patients, using either method.
G-banding karyotype analysis was performed in 3 patients. In patient no. 9, this analysis showed abnormal karyotypes (Table 4 ). In patient no. 6, there was only a single cell with an apparent chromosomal abnormality.
Response to treatment and survival
The median follow-up period was 19.5 months. Only patient no. 10 died, and this death resulted from autoimmune hemolytic anemia. The other 9 patients are alive, with or without disease. Treatment and outcome data for all patients are shown in Table 2 .
Six patients were treated with chemotherapy or allogeneic bone marrow transplantation, and 4 achieved complete response (CR). Three patients received only observation after splenectomy or thyroidectomy, and did not experience recurrence.
Discussion
In this study, we presented a new, distinct subgroup of T-cell lymphomas with good prognosis; this subgroup appears to be a subset of PTCL-NOS. The 10 patients with this condition showed similar histological findings, and the disease was characterized by infiltration of small lymphoid cells with slight nuclear atypia and low Ki-67 LI. Half of the patient samples showed the helper T-cell phenotype (CD4+), and the other half showed the cytotoxic phenotype (CD8+). Cytotoxic molecule positive PTCL-NOS was associated with several clinical factors that indicate poor prognosis [18, 19] . In this study, however, we could find no significant differences in clinicopathological data between samples with the cytotoxic phenotype and those with the helper T-cell phenotype. In addition, patient no. 8, who had the cytotoxic phenotype, is alive and without disease after splenectomy alone. This clinical behavior is unusual in general for PTCL-NOS. Actually, the cytotoxic markers become prognostic factors in PTCL-NOS, but in our present series, the cytotoxic markers might have displayed a different behavior.
It may be necessary to distinguish the disease observed in our patient series from T-cell large granular lymphocytic leukemia (T-LGL), T-cell prolymphocytic leukemia (T-PLL), and chronic lymphoproliferative disorders of NK cells (CLPD-NK) due to the fact that small lymphoid cells proliferate. T-LGL patients were distinguished from our patient series by their large granules and the displayed phenotype. T-PLL usually had elevated lymphocyte counts (>100 ×10 3 μl) and prominent nucleoli in lymphoid cells (1).
CLPD-NK are characterized by an increase in peripheral blood NK cells (>2 × 10 3 μl) and are positive for CD16 and CD56 (1). On the other hand, it may be necessary to distinguish our patient series from T-LGL, T-PLL, and chronic adult T-cell leukemia/lymphoma (ATLL) due to the fact that the clinical course was indolent. Our patient series can be distinguished by the T-LGL and T-PLL in their smear and the phenotype described above. ATLL showed monoclonal integration of HTLV-1. All patients in our series were negative for HTLV-1. Therefore, we excluded chronic ATLL.
While some patients were treated with chemotherapy and 1 patient received bone marrow transplantation, all patients, excluding patient no. 3, are alive, with or without disease, and 3 patients did not relapse after surgical resection. We thought that these clinical behaviors differentiated our series from the general PTCL-NOS population.
CD20, a selective marker for B-cells, was expressed in half of our patient series. The presence of CD20 is generally considered specific for the B-cell lineage on both benign and neoplastic lymphocytes. T-cell lymphoma with expression of CD20 is a rare, but well-recognized phenomenon, and CD20 expression has been reported in some patients [6, 7, [20] [21] [22] . Although the clinicopathological spectrum of CD20-positive T-cell lymphomas is still not well understood, this condition is known to occur frequently in elderly men and to show an aggressive clinical course in many patients [7] Another interesting result of the immunohistochemical staining was that all patient samples were found to be positive for CD45RO and CCR7, whereas 7 were positive for
CD62L. These antibodies are expressed in central memory T-cells (T CM ). Naive T-cells differentiate into lymphocytes of various type such as T CM , effector memory T-cells,
regulatory T-cells, and follicular helper T-cells after antigen stimulation [23] . In a study of helper T-cell differentiation of PTCL-NOS, it was reported that only 2 of 10 patients expressed both CCR7 and CD62L [24] . In contrast, 7 of the patients in our series showed samples that were positive for both of these antigens. This result suggests that this type of indolent T-cell lymphoma derives from organ-specific T CM . Furthermore, this characteristic suggests that this type of indolent T-cell lymphoma is localized to extranodal sites that are somewhat similar to MALT lymphoma [1, 25, 26] .
Although PTCL-NOSs are predominantly nodal lymphomas [27] , there was extensive extranodal site involvement in our patient series. PTCL-NOS at the extranodal sites, especially the spleen and the thyroid, might be associated with a high frequency of this type of indolent T-cell lymphoma. Physicians may need to pay careful attention to PTCL-NOS in these sites because of the possibilities of indolent T-cell lymphoma.
Xiao et al. reported a case of T-cell lymphoma with indolent clinical behavior that was
positive for CD20 [6] . Rahemtullah et al. described a 9-patient series of CD20-positive T-cell lymphomas, in which 1 patient presented with the same morphological and immunophenotypical characters as the patients in our present series [7] . These other 2 reports may concern the same subset of patients as does our series. Perry et al. reported 7 cases of indolent T-cell lymphoproliferative disease of the gastrointestinal tract [28] , and these patient samples consisted of small lymphoid cells with slightly irregular nuclei, clear cytoplasm, and low Ki-67 LI (5-10%). This lymphoproliferative disease might be similar to the one occurring in our patient series. To the best of our knowledge, ours is the first report to describe a clinicopathological analysis of this new, distinct subgroup of T-cell lymphomas.
In conclusion, indolent T-cell lymphoma has distinct morphological, immunophenotypical, and clinical outcomes. Therefore, it may need to be classified as an independent disease. More cases and long-term prognoses must be evaluated to clarify the pathophysiology of this subgroup.
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